The glycans deficiencies of macromolecular IgA1 is a contributory factor of variable pathological phenotypes of IgA nephropathy
- PMID: 16297170
- PMCID: PMC1809542
- DOI: 10.1111/j.1365-2249.2005.02949.x
The glycans deficiencies of macromolecular IgA1 is a contributory factor of variable pathological phenotypes of IgA nephropathy
Abstract
Recent evidence has suggested that IgA1-containing macromolecules and the glycosylation of IgA1 in sera from patients with IgAN might involve the pathogenesis of IgAN. However, whether the different histological phenotypes can be attributed or not to the aberrant glycosylation of macromolecular IgA1 has not yet been elucidated. The aim of the current study is to investigate the glycosylation of IgA1 molecules in serum IgA1-containing macromolecules and their association with pathological phenotypes of IgAN. Sera was collected from 40 patients with IgAN and 20 donors. Twenty patients had mild mesangial proliferative IgAN, the remaining 20 had focal proliferative sclerosing IgAN. Polyethylene glycol 6000 was used to precipitate the macromolecules from sera of patients and controls. Biotinylated lectins were used in an enzyme-linked immunosorbent assay (ELISA) to examine different glycans on IgA1 molecules. The alpha2,6 sialic acid was detected by elderberry bark lectin (SNA) and the exposure of terminal galactose (Gal) and N-acetylgalactosamine (GalNAc) were detected by Arachis hypogaea (PNA) and Vilsa villosa lectin (VVL), respectively. The IgA1 glycans levels corrected by IgA1 concentrations were compared between patients and controls. Reduced terminal alpha2,6 sialic acid of IgA1 (79.89 +/- 25.17 versus 62.12 +/- 24.50, P = 0.034) was demonstrated only in precipitates from sera of patients with focal proliferative sclerosing IgAN, compared with those from controls. Reduced galactosylation of IgA1 molecules in precipitates was demonstrated in patients with both mild mesangial proliferative IgAN and focal proliferative sclerosing IgAN compared with normal controls (24.52 +/- 18.71 versus 76.84 +/- 32.59 P = 0.000 and 33.48 +/- 25.36 versus 76.84 +/- 32.59 P = 0.000). However, no significant difference was found in IgA1 glycosylation in the supernatant between patients and normal controls (P > 0.05). The glycosylation deficiency of IgA1 existed only in serum IgA1-containing macromolecules of patients with IgAN, and was associated with the renal pathological phenotypes. This suggests that aberrant glycosylation of IgA1 in serum macromolecules might be a contributory factor in the pathogenesis of IgAN.
Similar articles
-
Aberrantly glycosylated serum IgA1 are closely associated with pathologic phenotypes of IgA nephropathy.Kidney Int. 2005 Jul;68(1):167-72. doi: 10.1111/j.1523-1755.2005.00390.x. Kidney Int. 2005. PMID: 15954905
-
Self-aggregated deglycosylated IgA1 with or without IgG were associated with the development of IgA nephropathy.Clin Exp Immunol. 2006 Apr;144(1):17-24. doi: 10.1111/j.1365-2249.2006.03026.x. Clin Exp Immunol. 2006. PMID: 16542360 Free PMC article.
-
Different glycosylation profile of serum IgA1 in IgA nephropathy according to the glomerular basement membrane thickness: normal versus thin.Am J Kidney Dis. 2003 Mar;41(3):558-64. doi: 10.1053/ajkd.2003.50117. Am J Kidney Dis. 2003. PMID: 12612978
-
IgA nephropathy and aberrant glycosylation of tonsillar, serum and glomerular IgA1.Adv Otorhinolaryngol. 2011;72:68-70. doi: 10.1159/000324609. Epub 2011 Aug 18. Adv Otorhinolaryngol. 2011. PMID: 21865693 Review.
-
Role of aberrant glycosylation of IgA1 molecules in the pathogenesis of IgA nephropathy.Kidney Blood Press Res. 2008;31(1):29-37. doi: 10.1159/000112922. Epub 2008 Jan 8. Kidney Blood Press Res. 2008. PMID: 18182777 Free PMC article. Review.
Cited by
-
A novel differential diagnostic model based on multiple biological parameters for immunoglobulin A nephropathy.BMC Med Inform Decis Mak. 2012 Jun 27;12:58. doi: 10.1186/1472-6947-12-58. BMC Med Inform Decis Mak. 2012. PMID: 22738421 Free PMC article.
-
Diagnostic and prognostic value of galactose-deficient IgA1 in patients with IgA nephropathy: an updated systematic review with meta-analysis.Front Immunol. 2023 Aug 21;14:1209394. doi: 10.3389/fimmu.2023.1209394. eCollection 2023. Front Immunol. 2023. PMID: 37671165 Free PMC article.
-
Aberrant IgA1 Glycosylation in IgA Nephropathy: A Systematic Review.PLoS One. 2016 Nov 21;11(11):e0166700. doi: 10.1371/journal.pone.0166700. eCollection 2016. PLoS One. 2016. PMID: 27870872 Free PMC article.
-
Differential binding characteristics of native monomeric and polymeric immunoglobulin A1 (IgA1) on human mesangial cells and the influence of in vitro deglycosylation of IgA1 molecules.Clin Exp Immunol. 2007 Jun;148(3):507-14. doi: 10.1111/j.1365-2249.2007.03374.x. Epub 2007 Mar 26. Clin Exp Immunol. 2007. PMID: 17386074 Free PMC article.
-
The Tn antigen-structural simplicity and biological complexity.Angew Chem Int Ed Engl. 2011 Feb 18;50(8):1770-91. doi: 10.1002/anie.201002313. Epub 2011 Jan 21. Angew Chem Int Ed Engl. 2011. PMID: 21259410 Free PMC article. Review.
References
-
- D'Amico G. The commonest glomerulonephritis in the world: IgA nephropathy. Q J Med. 1987;64:709–27. - PubMed
-
- Donadio JV, Grande JP. Immunoglobulin A nephropathy: a clinical perspective. J Am Soc Nephrol. 1997;8:1324–31. - PubMed
-
- Donadio JV, Grande JP. Immunoglobulin A nephropathy. N Engl J Med. 2002;347:738–48. - PubMed
-
- Valentijn RM, Radl J, Haaijman JJ, et al. Circulating and mesangial secretory component-binding IgA1 in primary IgA nephropathy. Kidney Int. 1984;26:760–6. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous